The effect of oral doxantrazole on allergen-induced bronchospasm.
The protective effect of 200 mg doxantrazole given orally on allergen-induced bronchoconstriction has been compared with 20 mg inhaled disodium cromoglycate (DSCG) in 15 patients with bronchial asthma and immediate-type hypersensitivity. Only four out of the 15 patients showed a significant inhibition of their bronchoconstriction after the oral intake of doxantrazole. Nine patients were significantly protected by 20 mg DSCG. All patients responding to doxantrazole also responded well to DSCG.
D000284:Administration, Oral; D000293:Adolescent; D000328:Adult; D000485:Allergens; D001393:Azoles / Q000627:therapeutic use*; D001986:Bronchial Spasm / Q000188:drug therapy* / Q000209:etiology / Q000503:physiopathology; D004205:Cromolyn Sodium / Q000627:therapeutic use; D004341:Drug Evaluation; D005260:Female; D005541:Forced Expiratory Volume; D006801:Humans; D008297:Male; D013777:Tetrazoles / Q000008:administration & dosage / Q000627:therapeutic use*
D000485:Allergens; D001393:Azoles; D013777:Tetrazoles; D004205:Cromolyn Sodium